急性冠状动脉综合征患者对阿司匹林和氯吡格雷低反应性的研究进展

不稳定斑块破裂、血栓形成是急性冠状动脉综合征的主要病理基础。对于急性冠状动脉综合征患者,尤其是准备接受经皮冠状动脉介入术的患者,许多大规模临床试验已经证实阿司匹林和氯吡格雷联合用药,不但能降低高危心血管危险因素患者的心血管事件发生率,而且可以显著减少经皮冠状动脉介入术围手术期缺血性并发症的发生。然而,临床观察发现,接受标准化阿司匹林和氯吡格雷治疗的患者中大约有1%~45%仍发生心血管事件[1]。这一现象表明,不同个体对抗血小板药物治疗反应性不同,因此,抗血小板药物治疗"抵抗"和"低反应性"成为目前临床研究的热点。

Aspirin and Clopidogrel Low Responsiveness in Acute Coronary Syndrome

The rupture of unstable plaque and formation of thrombi is the basic pathological progression of acute coronary syndrome.Increasing numbers of clinical trials have shown that aspirin and clopidogrel treatments can reduce the prevalence of cardiovascular events like acute coronary syndrome in high risk patients,as well as the incidence of ischemic events in patients ready for percutaneous coronary intervention.However,there are approximately 1%~45% patients treated with aspirin and clopidogrel who still have ischemic events[1].Therefore,the variable responsiveness of patients treated with antiplatelet drugs has become an area of interest in clinical research.